Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-Simile study).

The short version

This randomized, double-blind, placebo-controlled trial with 86 analyzed participants explored whether a homeopathic remedy could help people recover faster from mild COVID-19 while isolating at home in Brazil. Homeopathy is a medical system built on the "principle of similars" - the idea that a highly diluted substance capable of causing symptoms in a healthy person can treat similar symptoms in someone who is sick. The remedy tested, Natrum muriaticum (a homeopathic preparation of sodium chloride, common salt), was prepared using Samuel Hahnemann's fifty-millesimal (LM) method: repeated 1:50,000 dilutions with vigorous shaking (succussion) between steps, governing how homeopaths believe a remedy's potency rises as its material dose falls. Adults with a positive PCR test for SARS-CoV-2 and flu-like symptoms were randomly assigned to take drops of Natrum muriaticum LM2 or an identical-looking placebo every six hours (more often if symptoms were severe) during home isolation. Researchers tracked recovery by phone and WhatsApp, asking participants to rate 15 to 17 symptoms - including cough, fatigue, and loss of smell or taste - on a 0-to-3 severity scale, then combined these into a daily symptom score analyzed with Kaplan-Meier survival curves, the statistical method used to track time-to-event outcomes like recovery. The main result was a null one: time to full symptom recovery did not differ significantly between the homeopathy and placebo groups (P = 0.56 overall, P = 0.06 among the most symptomatic participants) - homeopathy showed a numerically shorter median recovery time (3 days versus 6 days) in the sicker subgroup, but the gap was not statistically reliable. A secondary analysis told a more encouraging, though still tentative, story: among participants who started with a high symptom burden, those taking homeopathy reached a 50% reduction in symptoms significantly faster than those on placebo (P = 0.04), improving roughly 0.9 days sooner over the first five days (P = 0.022) - though this edge disappeared by day 7 and day 10, suggesting it may reflect the natural course of a self-limiting illness rather than a true treatment effect. Hospitalization was numerically lower with homeopathy (2.4% versus 6.8%) but not statistically significant, and side effects were mild and similar between groups. For patients and clinicians, this trial does not provide evidence to recommend homeopathic Natrum muriaticum LM2 as a COVID-19 treatment - the confidence intervals around the promising secondary findings were too wide to draw firm conclusions, and the study fell short of its planned 90-participant sample after dropouts left 86. Baseline differences between groups, including more respiratory disease in the homeopathy arm, add further uncertainty. The authors frame this as a pioneering but inconclusive first step, calling for larger, more targeted trials - particularly in patients with more severe symptoms at enrollment - before homeopathy's role in COVID-19 care can be assessed.

Key findings

• In this randomized, double-blind, placebo-controlled trial of 86 adults with mild COVID-19, the homeopathic remedy Natrum muriaticum LM2 did not significantly speed overall recovery compared to placebo (P = 0.56).
• Among participants who started with more severe symptoms, those taking the homeopathic remedy reached a 50% reduction in symptoms significantly faster than those on placebo (P = 0.04), improving about 0.9 days sooner in the first five days of treatment.
• That early advantage disappeared by days 7 and 10, which the researchers say may reflect the natural course of a self-limiting illness rather than a true drug effect.
• Natrum muriaticum LM2 appeared safe, with side effects such as transient nausea or discouragement reported in only a few participants, at rates similar to or lower than the placebo group.
• Because the trial enrolled fewer participants (86) than its planned sample size (90) and produced wide confidence intervals around its secondary findings, larger studies focused on more symptomatic patients are needed before drawing conclusions about effectiveness.

Common questions